Semaglutide protects against diabetes-associated cardiac inflammation via Sirt3-dependent RKIP pathway

Area of Science:

• Cardiology
• Endocrinology
• Molecular Biology

Background:

• Glucagon-like peptide-1 receptor agonists (GLP-1RAs) show cardiovascular benefits in diabetes.
• Semaglutide, a novel GLP-1RA, reduces cardiovascular event risk.
• Mechanisms of GLP-1RA cardioprotection in diabetic cardiomyopathy are unclear.

Purpose of the Study:

• Investigate semaglutide's therapeutic potential in diabetic cardiomyopathy.
• Elucidate the molecular mechanisms underlying semaglutide's cardioprotective effects.

Main Methods:

• Diabetic mice (high-fat diet/streptozotocin) were treated with semaglutide.
• Animal and cell experiments analyzed cardioprotective mechanisms.
• Human diabetic heart tissues were examined for RKIP and TBK1-NF-κB pathway activity.

Main Results:

• Semaglutide improved cardiac function, reduced fibrosis, oxidative stress, and apoptosis in diabetic mice.
• Semaglutide attenuated cardiac inflammation by restoring Raf kinase inhibitor protein (RKIP) expression and inhibiting the TANK-binding kinase 1 (TBK1)-NF-κB pathway.
• This anti-inflammatory effect involved Sirtuin 3 (Sirt3) and cAMP/PKA signaling, not glucose lowering, and was observed in human diabetic hearts with decreased RKIP.

Conclusions:

• Semaglutide offers cardioprotection in diabetic heart failure by alleviating inflammation.
• The Sirt3-dependent RKIP signaling pathway is crucial for semaglutide's anti-inflammatory action.
• Targeting this pathway may represent a therapeutic strategy for diabetic cardiomyopathy.